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The G protein coupled receptors (GPCRs) have been considered as one of the largest
families of validated drug targets, which involve in almost overall physiological functions
and pathological processes. Meanwhile, Alzheimer’s disease (AD), the most common
type of dementia, affects thinking, learning, memory and behavior of elderly people,
that has become the hotspot nowadays for its increasing risks and incurability. The
above fields have been intensively studied, and the link between the two has been
demonstrated, whereas the way how GPCRs perturb AD progress are yet to be
further explored given their complexities. In this review, we summarized recent progress
regarding the GPCRs interacted with β-site APP cleaving enzyme 1 (BACE1), a key
secretase in AD pathogenesis. Then we discussed the current findings on the regulatory
roles of GPCRs on BACE1, and the possibility for pharmaceutical treatment of AD
patients by the allosteric modulators and biased ligands of GPCRs. We hope this
review can provide new insights into the understanding of mechanistic link between
GPCRs and BACE1, and highlight the potential of GPCRs as therapeutic target
for AD.
Keywords: G protein-coupled protein (GPCR), Alzheimer’s disease (AD), β-site APP cleaving enzyme 1 (BACE1),
allosteric modulator, biased ligand
INTRODUCTION
G protein coupled receptors (GPCRs) are integral membrane proteins that are used by cells
to convert extracellular signals into intracellular responses, including responses to hormones,
neurotransmitters, as well as responses to vision, olfaction and taste signals. These receptors
form a superfamily of membrane proteins comprising of five distinct families on the basis of
their sequences and structural similarities: rhodopsin (family A), secretin (family B), glutamate
(family C), adhesion and Frizzled/Taste2 (Fredriksson et al., 2003; Rosenbaum et al., 2009). They
all share common structural motifs in which seven transmembrane (TM) helices are connected
to three extracellular loops and three intracellular loops. However, despite structural similarities,
GPCRs have unique combinations of signal-transduction activities involving G protein dependent
signaling pathways, as well as G protein-independent signaling pathways and complicated
regulatory processes (Azzi et al., 2003; Rosenbaum et al., 2009; Rajagopal et al., 2010).
Numerous studies have presented evidence that implicate GPCRs in the pathogenesis
of Alzheimer’s disease (AD) and in multiple stages of the hydrolytic processing of amyloid
protein precursor (APP), a precursor protein involved in the formation of amyloid plaques
found in AD patients’ brain (Thathiah and De Strooper, 2009, 2011; Wisely et al., 2014).
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Indeed accumulated data have shown that GPCRs can bind to
β-secretase (β-site APP cleaving enzyme 1, BACE1) and
γ-secretase which are key enzymes in the hydrolytic processing
of APP (Liu et al., 2013; Nelson and Sheng, 2013; Thathiah et al.,
2013). However there is currently no cure for AD and the hope
for a new treatment has fallen short as the hottest inhibitors
targeting BACE1 and γ-secretase haven’t been approved by the
FDA due to the fact that they are not specific enough as they
can also inhibit the normal biological functions of secretases.
Therefore, the development of new therapeutic targets aimed at
GPCRs could be a promising method to maintain the effect and
control the side effects of inhibitors based on biased ligands or
allosteric modulators (Rajagopal et al., 2010; Nickols and Conn,
2014; Violin et al., 2014).
The main purpose of this review is to provide an overview
of the interaction between GPCRs and BACE1. We will firstly
summarize the structures and signaling pathways of GPCRs, then
address the reported implication of GPCRs in the pathologic
process of AD, focusing on BACE1 related GPCRs, and
also discuss the current findings on the regulatory roles of
GPCRs in the pathological progression of AD, as well as the
implication of GPCRs for pharmaceutical treatment of AD
patients.
A PROFILE OF GPCRs
GPCRs are encoded by nearly 800 distinct genes in the human
genome and form the largest TM receptor family found in
humans (Bockaert and Pin, 1999). It has been estimated that
more than half of all modern drugs are targeted at these receptors
(Hopkins and Groom, 2002). Nevertheless, these developed
drugs only target a very small number of GPCRs, leaving an
enormous potential for drug developments within this field
(Fredriksson et al., 2003).
A GPCR is basically composed of three parts: the extracellular
region, the TM region, and the intracellular region. The
extracellular region contains N terminus and three extracellular
loops (ECL1–ECL3); the TM region contains seven TM α-helices
(TM1–TM7); the intracellular region contains three intracellular
loops (ICL1–ICL3) and an intracellular amphipathic short
α-helix (H8) lying perpendicular to the membrane plane, and
the C terminus (Venkatakrishnan et al., 2013). In a broad sense,
the extracellular region modulates ligand access, the types of
which can vary tremendously, ranging from small molecules
to large proteins. GPCRs can transduct signals received from
messengers such as ions, organic odorants, amines, peptides,
proteins, lipids, nucleotides, and even photons (Rosenbaum
et al., 2009); the TM region forms the structural core, binds
to ligands and transduces this information to the intracellular
region through conformational changes, and the intracellular
region interfaces with cytosolic signaling proteins. The main
feature of GPCRs is to interact with G proteins. GPCRs can
bind to different isoforms of G proteins: Gs, Gq/11, Gi, G12/13
(Ferguson, 2007; Ritter and Hall, 2009) and activate a number
of alternative signaling cascades inside cells, enabling functional
diversities (Fredriksson et al., 2003). For details of GPCR-
dependent signaling pathways see Figure 1. The predominant
FIGURE 1 | Model of GPCRs mediated signaling pathways. In classical
model, heterotrimeric G proteins (α, β, γ subunits) mediate signal transduction
via the receptor. Signal transduction initiated when ligands bind to GPCRs.
The resulting conformation change promotes the exchange of GDP for GTP
on the Galpha subunit of G proteins. Gs activates AC leading to the
production of cAMP in cells, then cAMP binds to the regulatory subunit of
PKA, regulating the phosphorylation of the GPCR and leading the process of
desensitization of GPCR. PKA can regulate the level of CREB (Zeitlin et al.,
2011) and mediates MAPK ERK pathway (New and Wong, 2007). Gq/11
controls the activity of PLC, which hydrolyzes PIP2 to generate IP3 and DAG.
IP3 and DAG in turn lead to an increase in the intracellular concentrations of
free Ca2+, regulation of NFκB (Arendash et al., 2009) and the activation of a
number of protein kinases and pathways, including PKC/MAPK/ERK (Ritter
and Hall, 2009). GPCR activate PI3K/Akt cascades through Gβγ (New and
Wong, 2007). Gi inhibits AC, and G12/13 is suggested to activate GSK3 in
neuronal cells (Sayas et al., 2002a,b). GSK3 is involved in tau phosphorylation
with regard to AD pathology (Ly et al., 2013). And Akt and PKC can inhibit
GSK3 activity (New and Wong, 2007; Langmead et al., 2008). Abbreviations:
GPCR(s), G protein-coupled receptor(s); GDP, guanosine diphosphate; GTP,
guanosine triphosphate; AC, adenyl cyclase; cAMP, cyclic adenosine
monophosphate; PKA, protein kinase A; CREB, cAMP response
element-binding protein; MAPK, mitogen-activated protein kinase; ERK,
extracellular signal-regulated kinase; PLC, phospholipase C; PIP2,
phosphatidylinositol 4, 5-bisphosphate; IP3, inositol triphosphate; DAG,
diacylglycerol; NFκB, nuclear factor kappa-light-chain-enhancer of activated B
cells; PKC, protein kinase C; PI3K, phosphotidylinositol 3-kinase; Akt, protein
kinase B; GSK3, glycogen synthase kinase-3; AD, Alzheimer’s Disease.
signaling pathway have been revealed from early studies of
agonist-activated human β2 adrenergic receptor (β2AR) binding
to Gs, the stimulatory G protein for adenylyl cyclase. However,
it is now known that the β2AR couples to the G protein
Gi (Daaka et al., 1997), as well as activating G protein-
independent pathways through β-arrestins (Azzi et al., 2003), a
kind of scaffolding proteins mediating receptor desensitization
and internalization (Rajagopal et al., 2010), and possibly other
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cellular signaling proteins. In addition, these activities are
further complexified by factors such as GPCR oligomerization,
localization to specific membrane compartments and resulting
in differences in their lipid-bilayer composition (Rosenbaum
et al., 2009). It was originally thought that most ligands bound
to GPCRs have balanced or unbiased activities for signaling
through β-arrestins and G protein pathways, however, some
receptor-ligand systems and some allosteric modulators display
biased signaling (see ‘‘Discussion’’ Section below), which have
important implications for the design of therapeutics (Rajagopal
et al., 2010).
To provide insights into the structural and functional diversity
of GPCRs, the resolution of structure is necessary. However
they have been proven to be difficult to obtain, typically
requiring considerable time and investment (Venkatakrishnan
et al., 2013). Indeed, GPCRs are naturally produced but only
in very small quantities and often have short half-lives until
degradation occurs in cells. Since GPCRs are membrane-bound
proteins, indicating that they contain hydrophobic parts, thus
experimental determination of their 3D structures is still an
extremely difficult task (Warne et al., 2008). The first GPCR to
yield molecular structure data was unliganded bovine rhodopsin
purified from native tissue because of its high natural abundance
in retina (Palczewski et al., 2000). We summarized the resolved
GPCRs in Table 1. Data were collected from Protein Data Bank.
GPCRs AND AD
AD is the most common neurodegenerative disorder afflicting
around 24.0 million people worldwide, the morbidity rate of
which rises dramatically as people get older (Erb et al., 2015).
The pathological hallmark of AD is the extracellular deposition
of beta amyloid peptide (Aβ), the oligomeric soluble forms of
which are believed to be a key point for neuronal dysfunction,
synapse loss, neurofibrillary degeneration (Das et al., 2016). Aβ
comes from the amyloidogenic cleavage of APP, for details, see
Figure 2.
Many reports presented evidence that GPCRs were related
to AD (Blalock et al., 2004; Thathiah and De Strooper, 2009,
2011; Conn et al., 2014; Huang et al., 2015). Blalock et al.
(2004) published that an alteration of the gene expression
profile occurs in AD patients’ postmortem brains obtained by
cDNA microarray analysis. Analysis of the gene expression
profile of AD patients with different pathological severity
vs. normal age-matched controls showed that the levels of
transcripts from a number of GPCR genes changed, among
which were inflammation associated GPCRs, hormone receptors,
neurotransmitter receptors and some others. For example,
arginine vasopressin receptor 1A, dopamine receptor D2 (D2R),
metabotropic glutamate receptor type 6 (mGluR6), histamine
H4 receptor, G protein-coupled receptor 2 (GPR2) and some
others were upregulated; while cannabinoid receptor type
1, gamma-aminobutyric acid receptors, 5-hydroxytryptamine
receptor 1E/2A, parathyroid hormone 2 receptor, orphan G
protein-coupled receptor 22 (GPR22) and some others were
downregulated (Blalock et al., 2004). Given that the change of
expression levels of GPCRs would have an effect on the related
biological processes, these observations suggested a potential role
of GPCR in the pathological progression of AD, which requires
further investigation (Blalock et al., 2004). Until now, numerous
promising works have been done to connect GPCRs and AD
pathology based on three hypotheses: the Cholinergic hypothesis,
the Tau hypothesis and the Amyloid hypothesis (Thathiah and
De Strooper, 2009, 2011; Wisely et al., 2014).
We summarize the GPCRs involved in AD in Table 2.
Most GPCRs in family A are classified as binding small ligands
TABLE 1 | GPCRs that have resolved crystal structures in a timeline.
Year Proteins
2000 Bovine rhodopsin (1F88), Palczewski et al. (2000)
2007 Human β2AR (2RH1), Rasmussen et al. (2007)
2008 Turkey β1AR (2VT4), Warne et al. (2008); Squid rhodopsin (2Z73), Murakami and Kouyama (2008); Human A2A AR (3EML), Jaakola et al. (2008)
2010 Human CXCR4 (3ODU), Wu et al. (2010); Human D3R (3PBL), Chien et al. (2010)
2011 Human H1R (3RZE), Shimamura et al. (2011)
2012 Human M2 AchR (3UON), Haga et al. (2012); Human S1PR (3V2Y), Hanson et al. (2012); Human M3 AChR (4DAJ), Kruse et al. (2012); Human KOR (4DJH),
Wu et al. (2012); Mouse MOR (4DKL), Manglik et al. (2012); Human N/O FQR (4EA3), Thompson et al. (2012); Mouse DOR (4EJ4), Granier et al. (2012); Rat
NTSR1 (4GRV), White et al. (2012); Human CXCR1 (2LNL), Park et al. (2012); Human PAR1 (3VW7), Zhang et al. (2012b)
2013 Human 5-HT2BR (4IB4), Wacker et al. (2013); Human 5-HT1BR (4IAR), Wang et al. (2013a); Human SMOR (4JKV), Wang et al. (2013b); Human CRFR1
(4K5Y), Hollenstein et al. (2013); Human GCGR (4L6R), Siu et al. (2013); Human CCR5 CR Tan et al. (2013)
2014 Human GluR1 (4OR2), Wu et al. (2014); Human P2YR12 (4NTJ), Zhang et al. (2014); Human GluR5 (4OO9), Doré et al. (2014); Human GPR40 (4PHU),
Srivastava et al. (2014)
2015 Human OX2 (4S0V), Yin et al. (2015); Human DOR (4RW4), Fenalti et al. (2015); Human P2YR1 (4XNW), Zhang et al. (2015a); Human AT1R (4YAY), Zhang
et al. (2015b)
Abbreviations: GPCRs, G protein-coupled receptors; β1/β2AR, β1/β2 adrenergic receptor; A2A AR, adenosine A2A receptor; CXCR4, C-X-C chemokine receptor type 4;
D3R, D3 dopamine receptor; H1R: histamine H1 receptor; M2/M3 AChR, M2/M3 muscarinic acetylcholine receptor; S1PR, sphingosine-1 phosphate receptor; K/M/DOR,
kappa/mu/delta opioid receptor; N/O FQR, nociceptin/orphanin FQ receptor; NTSR1, neurotensin receptor type 1; CXCR1, CXC chemokine receptor 1; PAR1, protease-
activated receptor; 5-HT1B/2BR, 5-hydroxytryptamine receptor type 1B/2B; SMOR, smoothened receptor; CRFR1, Corticotropin-releasing hormone receptor 1; GCGR,
glucagon receptor; CCR5 CR, C-C chemokine receptor type 5; GluR1/5, glutamate receptor type 1/5; P2YR1/12, purinergic G protein-coupled receptor 1/12; GPR40, G
protein-coupled receptor 40; OX2, Orexin receptor type 2; AT1R, Angiotensin II type 1 receptor.
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FIGURE 2 | Cleavage of amyloid precursor protein (APP). APP processes two different hydrolysis pathways: amyloidogenic pathway and non-amyloidogenic
pathway. Sequential cleavage of APP by α-secretase and γ-secretase generates a soluble amino terminal ectodomain of APP (sAPPα), the carboxy terminal
fragment C83, APP intracellular domain (AICD) and a short fragment p3. There is no production of beta amyloid peptide (Aβ) from this pathway. Sequential cleavage
of APP by β-secretase (BACE1) and γ-secretase generates sAPPβ, C99, AICD and Aβ (Thathiah and De Strooper, 2011).
within their TM core. Family B can bind mid-size peptide
hormones with their deep and open V-shaped crevice. Family
C is characterized by a large N-terminal domain which is
the recognition site for ligands (Katritch et al., 2013). Besides,
matching electrostatic properties among ligands and binding
pocket allows the discrimination between ligands of a wide range
of sizes. For example Kappa opioid receptor has highly acidic
patches at the extracellular side, which most likely interacts
with the basic C-terminus of dynorphin; in contrast, Mu
opioid receptor lacks negative surface potential reflecting the
uncharged nature of enkephalins (Manglik et al., 2012). Serine
and threonine residues in the C-terminal region and a serine-
rich sequence in ICL3 are potential sites for phosphorylation.
A recent research verified that site mutation at ICL3 on the
corticotrophin releasing factor receptor 1 (CRFR1) decreases the
interaction between CRFR1 and γ-secretase, and blocks CRF-
induced increase in total Aβ and Aβ40 but not Aβ42 (Park et al.,
2015).
GPCRs AND BACE1
BACE1, a 501 amino acid type 1 TM aspartic protease related
to the pepsin family, initiates Aβ generation and the resultant
cerebral amyloidosis: deposition of Aβ (for details, see Figure 2).
BACE1 catalytic domain contains two signature aspartic protease
motifs (Asp-Thr/Ser-Gly-Ser/Thr) that form the active site of
the enzyme and are oriented in the lumen of acidic intracellular
compartments for cleaving the β-secretase site of APP. The
highest concentrations of BACE1 can be found in neurons.
With the correct sequence specificity and at acidic pH optimum
for enzymatic activity, BACE1 undertakes processing of APP,
and increases Aβ generation (Yan and Vassar, 2014). BACE1
is predominantly localized in the tans Golgi network (TGN)
and endosomes. These acidic endosome compartments provide
a low pH environment, which is more favorable for BACE1
activity (Das et al., 2016). In the AD brain, the activity of
BACE1 has been shown to be up-regulated, but not its mRNA
levels (Yang et al., 2003). Several proteins, such as translation
initiation factor eIF2α (O’Connor et al., 2008), Golgi-localized
γ-ear-containing adenosine diphosphate (ADP)-ribosylation
factor binding proteins (GGAs; He et al., 2005), glycogen
synthase kinase 3 (GSK3; Ly et al., 2013), the reticulon/Nogo
family of proteins (He et al., 2004), and sortilins (Okada
et al., 2010), are implicated in the regulation of BACE1, but
the mechanisms, as well as their putative coordinated actions,
remain unclear. In the GPCR superfamily, M1 AChR (Jiang
et al., 2012), δ-opioid receptor (DOR; Teng et al., 2010), A2A
receptor (Arendash et al., 2006), are reported to regulate the
activity of BACE1. GPCR regulating proteins, such as GPCR-
associated sorting proteins (GASPs; Mishra and Heese, 2011),
small G proteins such as Rabs (Teng et al., 2010; Buggia-
Prévot et al., 2014) and ADP-ribosylation factor 6 (ARF6;
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TABLE 2 | GPCRs involved in AD.
GPCRs Families Relation to AD
M1 AChR Family A (sAPP↑, Aβ↓), Nitsch et al. (1992), Jones et al. (2008), and Jiang et al. (2012); (sAPP↑), Buxbaum et al. (1992); (BACE1↑),
Züchner et al. (2004); (M1 AChR knock-out transgenic mice APPSwedish/Indiana, Aβ↑), Davis et al. (2010); (BACE1↓, Aβ↓),
Caccamo et al. (2006)
M2 AChR Family A (BACE1↓), Züchner et al. (2004)
M3 AChR Family A (sAPP↑, Aβ↓), Nitsch et al. (1992); ( BACE1↑), Züchner et al. (2004)
mGluR1 Family C (C83, C99, Aβ40↑), Kim et al. (2010); (sAPP↑), Lee et al. (1995), Kirazov et al. (1997) and Nitsch et al. (1997)
mGluR2 Family C (tau phosphorylation↑), Lee et al. (2009); (C83, C99, Aβ42↑), Kim et al. (2010)
mGluR3 Family C (C83, C99, Aβ42↑), Kim et al. (2010)
mGluR5 Family C (C83, C99, Aβ40↑), Kim et al. (2010)
5-HT2R Family A (sAPP↑, Aβ↓), Nitsch et al. (1996); (Aβ↓), Arjona et al. (2002)
5-HT4R Family A (sAPPα↑, Aβ↓), Robert et al. (2001), Giannoni et al. (2013), Tesseur et al. (2013), and Pimenova et al. (2014)
5-HT6R Family A (Improved cognition and memory), Upton et al. (2008), Maher-Edwards et al. (2010), Rossé and Schaffhauser (2010), and
Benhamú et al. (2014)
DOR Family A (Aβ↓), Teng et al. (2010) and Cai and Ratka (2012)
Adrenergic Receptor Family A (Aβ↑), Ni et al. (2006) and Chen et al. (2014); (tau phosphorylation↑), Branca et al. (2014) and Wisely et al. (2014)
ATR Family A (Tau phosphorylation and neurodegeneration↑), (AbdAlla et al., 2009a,b); (memory↓), Ongali et al. (2014)
Adenosine Receptor Family A (Aβ↓), Canas et al. (2009), Espinosa et al. (2013), Giunta et al. (2014), Nagpure and Bian (2014), and Orr et al. (2015);
(BACE1↓, Aβ↓), Arendash et al. (2006)
CXCR2 Family A (Aβ↑), Bakshi et al. (2008, 2009, 2011)
CXCR3 Family A (plaque↑), Krauthausen et al. (2015)
CRFR1 Family B (Aβ↓), Justice et al. (2015); (tau hyperphosphorylation↓), Carroll et al. (2011) and Rissman et al. (2012); (hippocampal
synaptophysin level↑), Scullion et al. (2013)
PACR1 Family B (sAPPα↑), Kojro et al. (2006); (cognition↑), Rat et al. (2011) and Yang et al. (2015)
GPR3 Family A (Aβ↑), Thathiah et al. (2009) and Nelson and Sheng (2013)
P2Y receptor Family A (Aβ↑), Ajit et al. (2014) and Erb et al. (2015)
CX3CR1 Family A (amyloid plaque↓), Lee et al. (2010), Liu et al. (2010), Cho et al. (2011) and Condello et al. (2015)
CCR2 Family A (Aβ↓); El Khoury et al. (2007)
Abbreviations: GPCRs, G protein-coupled receptors; AD, Alzheimer’s Disease; M1/ M2/M3 AChR, M1/ M2/M3 muscarinic acetylcholine receptor; mGluR1/2/3/5,
metabotropic glutamate receptor type 1/2/3/5; 5-HT2/4/6R, 5-hydroxytryptamine receptor type 2/4/6; DOR: δ opioid receptor; ATR, angiotensin receptor; CXCR2/3, CXC
chemokine receptor 2/3; CRFR1, corticotrophin releasing factor receptor 1; PACR1, Pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type I; GPR3,
G protein-coupled receptor 3; P2Y receptor, purinergic G protein-coupled receptor; CX3CR1, CX3C chemokine receptor type 1; CCR2, C-C chemokine receptor type
2; sAPP, soluble amino-terminal ectodomain of amyloid precursor protein; sAPPα, soluble amino terminal ectodomain of APP cleaved by α-secretase; Aβ, beta amyloid
peptide; Aβ40/42, 40/42-amino acid beta amyloid peptide; BACE1, beta secretase; C83, 83-amino acid carboxy-terminal fragment; C99, 99-amino acid carboxy-terminal
fragment.
Sannerud et al., 2011) are also revealed to mediate BACE1
activity.
Muscarinic Acetylcholine Receptor
Introduction to Muscarinic Acetylcholine Receptor
The muscarinic acetylcholine receptors are members of the
family A GPCRs that are synthesized by cholinergic cells.
They are widely expressed in the central nervous system
where they control a variety of neuronal functions (Langmead
et al., 2008). The five subtypes of muscarinic acetylcholine
receptor (mAChR) are generally divided into two groups based
on signal transduction (Wess et al., 2007). M1, M3 and M5
mAChRs can activate phospholipase C (PLC) and mobilize
intracellular calcium through Gq/11, which is critical in neuronal
communication and synaptic plasticity. While M2 and M4
mAChRs are coupled to Gi and then inhibit adenylate cyclase
activity (Langmead et al., 2008) as well as several ion channels
such as N-methyl-D-aspartate receptor (NMDAR; Salter and
Kalia, 2004) and calcium channels (Zhou et al., 2008), leading
to the reduction of cyclic adenosine monophosphate (cAMP),
the inhibition of voltage-gated Ca2+ channels, and the increasing
efflux of K+, in general, leading to inhibitory effects (Odagaki
et al., 2014). mAChRs and ligand-gated ion channel nicotinic
(nAChR) together can mediate the actions of acetylcholine
(ACh). Both are important neurotransmitter receptors involved
in learning and memory (Thathiah and De Strooper, 2009).
Actually, commercial therapies for the treatment of AD approved
by the FDA are mainly acetylcholinesterase inhibitors (AChEI)
that are designed to boost levels of ACh. Since 1992, when
researchers found that activation of M1 and M3 AChR can
increase the release of soluble amino terminal ectodomain of
APP cleaved by α-secretase (sAPPα). In addition, mAChRs
have been intensively studied and revealed that the increase of
sAPPαwas accompanied by a decreased release of Aβ, suggesting
that normal cholinergic activity may suppress the formation of
potentially amyloidogenic derivatives (Nitsch et al., 1992). It
was speculated that mAChR regulates APP release by protein
kinase C (PKC) activation or an interaction of diacylglycerol
and calcium released from internal pools by inositol triphosphate
(IP3; Nitsch et al., 1992). The predominant mAChR in the
CNS is subtype 1, which is located in the cerebral cortex
and hippocampus, areas known to be vital for learning and
memory and to be the location where amyloid plaques form,
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resulting in neuron loss. As a consequence, M1 mAChR agonists
has been suggested as a promising novel approach to AD
therapy (Langmead et al., 2008; Conn et al., 2009; Melancon
et al., 2013). Xanomeline is a selective agonist of M1/M4
subtype, which provides the most significant human data for
treatment of AD (Bodick et al., 1997). Despite the fact that it
failed during phase-II clinical trial due to serious side-effects,
Xanomeline has been shown to have reasonable efficacy to
improve learning and short-term memory in AD patients (Conn
et al., 2009).
BACE1 Related Muscarinic Acetylcholine Receptors
Studies have demonstrated that mAChR can mediate the level of
BACE1 (Züchner et al., 2004; Jiang et al., 2012). The activation
of M1 and M3 mAChRs in SK-SH-SY5Y neuroblastoma cell line
by talsaclidine, a M1/M3-selective mAChR agonist, could up-
regulate BACE1 in a dose-dependent way after 3 h treatment.
In contrast, BACE1 expression was down-regulated by the
activation of M2 mAChR (Züchner et al., 2004). However, results
are controversial (Caccamo et al., 2006; Jiang et al., 2012).
Caccamo et al. (2006) investigated the therapeutic efficacy of
selective M1 mAChR agonist AF267B in the 3 × Tg-AD model
mice (human APP Swedish mutation, APPSwe, tauP30L, mutant
PS1M146V knockin) and found a significant decrease in BACE1
levels in the brain of AF267B treated mice vs. untreated 3 ×
Tg-AD mice. Conversely, administration of dicyclomine, an M1
mAChR antagonist, led to a notable increase in BACE1 levels
compared with phosphate-buffered saline (PBS)-injected mice
(Caccamo et al., 2006). A recent data also showed a dramatical
decrease of BACE1 protein levels instead of the mRNA levels
after over-expression of M1 mAChR into human embryonic
kidney (HEK)-APPSwe cells, a HEK cell line stably expressing
human APP Swedish mutations (Jiang et al., 2012). This process
is accompanied with a rise of sAPPα and a fall of Aβ, while there
is no effect on the level of full-length APP. The authors confirmed
the interaction between M1 mAChR and BACE1 by yeast two-
hybrid and co-immunoprecipitation experiments. They further
silenced M1 mAChR and the endogenous BACE1 was markedly
increased (Jiang et al., 2012).
Opioid Receptor
Introduction to Opioid Receptor
The opioid system modulates several physiological processes,
including analgesia, the stress response, the immune response
and the neuroendocrine function. Opioid receptors and opioid
peptides, vulnerable to AD, are widely expressed in the central
nervous system, including hippocampus and cortex, the brain
regions crucial for cognition. They play important roles in
synaptic activation, learning and memory. Administration of
opioid antagonists has been found to significantly improve
the memory of animals (Gallagher et al., 1983); thus, in
1980s, the opioid antagonist naloxone, which was approved
for the treatment of opioid overdose by the FDA in 1971,
was used in a double-blinded placebo-controlled clinical study
to test its potential effect on improving cognitive functioning
in individuals with probable AD (Reisberg et al., 1983).
However, later studies have failed to support the efficacy of
the nonselective antagonists naloxone or naltrexone in AD
(Tariot et al., 1986; Henderson et al., 1989). Given the distinct
and even opposing roles of DOR, κ-opioid receptor (KOR),
and µ-opioid receptor (MOR) in modulating animal behaviors,
such as response of locomotion, level of anxiety, depressive-
like behavior or alcohol intake in different opioid receptor
knockout mice (Kieffer and Gavériaux-Ruff, 2002), the overlap
between the distribution of opioid receptors and the location
of amyloid plaques in AD patients led us to postulate a
possible role of these three opioid receptors in the pathology
of AD.
BACE1 Related Opioid Receptors
Previous reports have shown that altered cell signaling of
opioid receptors is related to abnormal Aβ production and
AD pathogenesis (Reisberg et al., 1983; Tariot et al., 1986;
Henderson et al., 1989; Ni et al., 2006). Teng et al. (2010)
over-expressed DOR in HEK293T cell line and performed the
fluorogenic substrate assay to directly evaluate the effect of DOR
on secretase activities and found that 30 min after stimulation by
DOR agonist, BACE1 and γ-secretase activities were enhanced
to 143% and 156%, respectively, while the activity of α-secretase
was not affected. Pretreatment with DOR selective antagonist
naltrindole (NTI), on the other hand, blocked the enhancement
of BACE1 and γ-secretase activities by DOR agonist, indicating
that secretase activity enhancement depends on DOR activation
(Teng et al., 2010). Chronic treatment of APP/PS transgenic AD
model mice with NTI alleviated Aβ pathology and improved
cognitive deficits in spatial reference memory by reducing
activities of endogenous BACE1 and γ-secretase without any
changes in APP expression levels or Aβ clearance (Teng et al.,
2010).
Adenosine Receptor
Introduction to Adenosine Receptor
Adenosine is found in all cells including glia and neurons,
and plays important roles in the regulation of synaptic
transmission and neuronal excitability in the central nervous
system. Functional and molecular studies made it possible to
classify adenosine receptors as A1, A2A, A2B, and A3 subtypes
(Ribeiro and Sebastião, 2010). A1 receptors are highly enriched
in the CA1 region of hippocampus in a normal healthy
brain. A change in the pattern of A1 receptor expression
has been found in AD patients when compared with age-
matched control brains (Angulo et al., 2003). In addition,
activation of A1 receptors could lead to the production of
soluble APP, which was confirmed by the use of A1-selective
antagonist DPCPX (Angulo et al., 2003). Studies also revealed
that A1 receptors mediate tau phosphorylation, another key
factor for pathogenesis of AD besides Aβ, and its translocation
towards the cytoskeleton of neuroblastoma cells (Angulo et al.,
2003; Giunta et al., 2014). A marked increase in A1 receptor
immunoreactivity has been found in degenerating neurons
with neurofibrillary tangles and in dystrophic neurites of
Aβ plaques in the hippocampus and frontal cortex of AD
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(Angulo et al., 2003). Significant co-localizations of A1 receptors
and Aβ in senile plaques, as well as of A1 receptors and tau in
neurons with tau deposition, have been found (Angulo et al.,
2003; Giunta et al., 2014). The A2A receptor is also expressed
in the brain, where it has important roles in the regulation
of glutamate and dopamine release, making it a potential
therapeutic target for the treatment of neuronal diseases. A2A
receptors have low expression in healthy brain but this pattern
of expression and functionality can be changed in pathological
conditions.
BACE1 Related Adenosine Receptors
Arendash et al. reported a decrease of BACE1 and PS1
expression level in APP transgenic mouse hippocampal tissue
after long term administration of caffeine, a non-selective A1
and A2A adenosine receptor antagonist, to APPSwe transgenic
mice. Caffeine treatment also improved cognition and reduced
Aβ40 and Aβ42 generation of APPSwe mice (Arendash et al.,
2006). The authors then further provided evidence that
caffeine treatment can reverse cognitive impairment and they
developed insight into possible mechanisms involved in BACE1
suppression by caffeine (Arendash et al., 2009; Zeitlin et al.,
2011).
GPCR Regulating Proteins
Small GTPase
Small GTPase constitute a superfamily consisting of more
than 100 members. This superfamily is structurally classified
into at least five families: the Ras, Rho/Rac/Cdc42, Rab,
Sar1/ARF, and Ran families (Takai et al., 2001). Some Rabs
are expressed ubiquitously in human tissues, whereas others
are tissue-specific. Within cells, they are localized to the
cytosolic face of distinct intracellular membranes (Pfeffer, 2013;
Nagano et al., 2015). Functional loss of the Rab pathways
has been implicated in a variety of diseases, Rab5 and Rab7,
which control early and late endosome fusion respectively, are
selectively up-regulated in hippocampal neurons of individuals
with mild cognitive impairment and AD (Ginsberg et al.,
2010). In the team of Pei G, they observed the colocalization
of Rab7 and BACE1, Rab7 and BACE1/PS1 complex (Teng
et al., 2010). Further data from RNAi screening of all human
Rab-GTPase associate Rab11 with late onset AD (Udayar
et al., 2013). Recently, Buggia et al. reported that Rab11 is
critical for axonal sorting of BACE1, since BACE1 shows in
Rab11 positive endosomes, and impairment of Rab11 function
leads to a diminution of total and endocytosis BACE1 in
axons (Buggia-Prévot et al., 2014). Rab11 was revealed to
colocalize with BACE1 by direct visual images (Das et al.,
2016). Also ARFs are a family of small GTPases that are
involved in various aspects of membrane trafficking events.
ARF6 is demonstrated to mediate the endosomal sorting of
BACE1. Furthermore, the sorting of newly internalized BACE1
from ARF6-positive towards Rab GTPase 5 (Rab5)-positive
early endosomes depends on the carboxyterminal short acidic
cluster-dileucine motif of BACE1 (Sannerud et al., 2011).
Ras homolog enriched in brain (Rheb) was demonstrated to
regulate BACE1 stability and activity by reducing the half-
life of BACE1 in a GTP-dependent manner (Shahani et al.,
2014).
GPCR-Associated Sorting Protein
GPCR-associated sorting protein (GPRASP family protein) has
been shown to preferentially sort a number of native GPCRs
to the lysosome for degradation after endocytosis. p60TRP, also
known as GASP3 or BHLHB9, is a kind of GPRASP. P60TRP
is localized in both the cytoplasm and the nucleus of cells and
has been predominantly observed in the CNS, particularly in
the brain. Among the many distinguishing features of p60TRP,
one of the most noteworthy is that it contains a potential myc-
type basic helix-loop-helix (bHLH) domain at its C-terminus;
this domain is a protein structural motif that characterizes a
family of transcription factors (Heese, 2013). Since 2004, Heese
Klaus with the lab members have discovered p60TRP gene as
a potential rescue factor against cell death by applying a death
trap method (Heese et al., 2004). Increased expression of p60TRP
induces the dephosphorylation of APP, which inhibits BACE1
activity and causes reduced APP intracellular domain (AICD)
signaling in p60TRP-overexpressing cells (Mishra and Heese,
2011).
DISCUSSION
How do GPCRs regulate the levels of BACE1? Despite countless
research studies being performed, the answer remains to be
elucidated. However, the available documents provide us insights
to the role of GPCRs in mediating BACE1 by mechanisms that
fall into the following categories: (i) GPCRs activation stimulates
G protein-dependent signaling pathway, which finally alters the
expression level of BACE1; (ii) GPCRs activation mediates
the degradation of BACE1; and (iii) GPCRs activation regulates
the trafficking of BACE1.
Impact of GPCRs Signaling Pathway on
BACE1 Expression
The classical G protein signaling pathway (see Figure 1) is
considered to be an explanation for the regulation of BACE1 and
other key proteins in AD (Thathiah and De Strooper, 2011). The
concurrence of changes in some molecules in the pathway and
changes in key proteins in AD after activation of GPCRs seems
to be more than coincidental.
A previous study suggested that the mitogen-activated
protein kinase (MAPK)/extracellular signal-regulated kinase
(ERK) pathway is involved in the regulation of BACE1 by
M1 mAChR (Sinha et al., 1999). One effect of MAPK/ERK
activation is to alter the translation of mRNA to proteins.
Züchner et al. showed that agonists binding to M1-/M3- mAChR
can up-regulate BACE1 expression through activation of both
PKC and MAPK signaling cascades. In contrast, studies have
shown BACE1 expression is down-regulated by the activation of
M2- mAChR- and protein kinase A (PKA)-mediated pathways
(Züchner et al., 2004). Studies also showed that caffeine treatment
can significantly increase PKA activity in Tg mice and striatum
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of APPSwe mice (Arendash et al., 2009; Zeitlin et al., 2011).
The author proposed that enhanced PKA activity inhibits
cRaf-1 (a proto-oncogene serine/threonine-protein kinase) by
phosphorylation at serine259, decreasing nuclear factor kappa-
light-chain-enhancer of activated B cells (NFκB) activity and
the expression of NFκB-controlled genes such as BACE1 in the
hippocampus of treated AD Tg mice (Arendash et al., 2009).
In addition, the results showed that caffeine increases cAMP
response element-binding protein (CREB) phosphorylation at
Ser133 in the striatum and decreases c-Jun N-terminal kinase
(JNK)/ERK phosphorylation in the striatum and cortex of
APPSwe mice (Zeitlin et al., 2011). And Caccamo et al. (2006)
demonstrated a significant decrease in BACE1 levels in the
brain of AF267B treated mice and compared to untreated 3
× Tg-AD mice, while a dramatic increase in BACE1 levels
in the brain of dicyclomine treated mice. Accompanied with
the changes of BACE1, a marked rise of phosphorylated
ERK in the brains of AF267B treated mice, and a significant
reduction of that in the brains of dicyclomine treated mice, in
comparison with PBS-treated mice, while levels of ERK were
not changed in the brain of AF267B or dicyclomine treated
mice (Caccamo et al., 2006). This is consistent with the fact that
phosphorylated ERK represents functional ERK. Paradoxically,
recent data suggested M1 mAChRs can interact with BACE1
and decrease BACE1 to reduce Aβ, in which process ERK
and phosphoinositide 3-kinase (PI3K) signaling pathway is not
involved (Jiang et al., 2012). Also, G protein pathway is not
involved in the DOR activation-induced rise of BACE1 (Teng
et al., 2010).
Furthermore, comparable findings were observed regarding
γ-secretase and GPCRs (Ni et al., 2006; Thathiah et al.,
2009). Pei G and his team ruled out the involvement of
β2-adrenergic receptor (β2-AR)-induced G protein-dependent
signaling pathway. Initially, they used β2-AR mutants, which
could not activate G protein, and found that the uncoupling of
the receptors with G protein did not affect the enhancement
of γ-secretase. Then they treated cells with some reagents that
mimic G protein activation and found none of them could
enhance γ-secretase activity (Ni et al., 2006). Thathiah et al.
(2009) demonstrated that the orphan G protein-coupled receptor
3 (GPR3) could increase Aβ generation by enhancing γ-secretase
activity independent of GPCR signaling pathway with similar
methods. GPR3, G protein-coupled receptor 6 (GPR6) and G
protein-coupled receptor 12 (GPR12) shared signaling triggered
by sphingosine-1 phosphate receptor (S1PR; Uhlenbrock et al.,
2002). They are involved in cAMP signaling pathway (Hinckley
et al., 2005; Tanaka et al., 2007).
Impact of GPCRs on BACE1 Degradation
BACE1 has been reported to be degraded by the lysosomes and
ubiquitin-proteasome pathway (Qing et al., 2004; Koh et al.,
2005; Kang et al., 2012; Wang et al., 2012), and accelerating
BACE1 degradation by ubiquitin carboxyl-terminal hydrolase
L1 (UCHL1) reduces 99-amino acid carboxy-terminal fragment
(C99) and Aβ production (Zhang et al., 2012a). Researchers from
a lab of Xiamen University observed the increase and decrease of
BACE1 after activation and inhibition ofM1 mAChR,meanwhile
the mRNA levels of BACE1 remained stable. They suggested
that the effects of BACE1 by M1 mAChR is probably mediated
by its degradation (Jiang et al., 2012). When cells were treated
with proteasome inhibitor lactacystin, it was shown that over-
expression of M1 mAChR could result in a marked increase in
the level of ubiquitinated BACE1. When cells were treated with
a lysosome inhibitor NH4Cl, it was found that BACE1 levels also
increases, but no differences between cells of M1 mAChR over-
expression treatment, suggesting that BACE1 could be degraded
by both lysosome and ubiquitin-proteasome pathway, while
M1 mAChR-mediated BACE1 degradation is mainly through
ubiquitin-proteasome pathway (Jiang et al., 2012). Whereas the
details about how GPCRs regulate BACE1 degradation needs
further investigation.
Impact of GPCRs on BACE1 Trafficking
BACE1 cycles between the Golgi apparatus and the plasma
membrane, traveling through endosomes on the way. Substantive
evidence indicated that APP processing by BACE1 is dependent
on the intracellular trafficking of this enzyme (He et al., 2004;
Tesco et al., 2007; Sannerud et al., 2011; Chia et al., 2013;
Buggia-Prévot et al., 2014). For example, BACE1 can interact
with reticulon/Nogo proteins, whose increased expression can
block BACE1 in the endoplasmic reticulum (ER) that has a
neutral pH environment and thus inhibiting BACE1 activity in
Aβ generation (He et al., 2004; Murayama et al., 2006). Depletion
of GGA proteins increases the accumulation of BACE1 in acidic
early endosomes resulting in enhanced BACE1 stability and APP
cleavage (Tesco et al., 2007). Nonetheless, knowledge of the
intracellular trafficking pathway of internalized BACE1 remains
in doubt.
Alteration of BACE1 in Plasma Membrane
Many GPCRs, BACE1, γ-secretase, and Aβ generation are
localized in lipid raft (Thathiah et al., 2009; Teng et al., 2010;
Park et al., 2015). Researches have revealed that GPCRs activation
could increase the distribution of BACE1 and γ-secretase in
lipid rafts (Teng et al., 2010). What’s more, they proposed
a model of GPCR/BACE1/γ-secretase complex, based on the
results of immunoprecipitation experiments. They then verified
that disruption of lipid raft by removing cholesterol from the
cells could significantly reduce the interaction between DOR
and BACE1 or γ-secretase, indicating that the association is
dependent on the integrity of lipid raft (Teng et al., 2010).
Likewise, GPR3 appears to promote the trafficking of γ-secretase
to the cell surface and increased localization in detergent-
resistant membranes (DRMs), which eventually leads to an
increase in Aβ generation (Thathiah et al., 2009).
Alteration of BACE1 Internalization
Clathrin-mediated endocytosis is the primary process of GPCRs
and APP internalization, while internalization of BACE1
occurs at a slower bulk flow rate (Ni et al., 2006; Sannerud
et al., 2011). Pei G and his group has confirmed that DOR
activation leads to an enrichment of BACE1 and γ-secretase
in endocytic compartments. They suspected whether DOR
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could direct the endocytosis of secretases, so they performed
confocal fluorescence time-lapse microscopy with HEK293T
cells expressing fluorescently tagged BACE1 and PS1 (catalytic
subunit of γ-secretase) together with tagged DOR, they indeed
detected a strong colocalization of the three proteins (Teng et al.,
2010).
Alteration of BACE1 in Endosomes
Mechanistic studies have revealed that activated DOR
can facilitate the endocytic sorting of secretases for APP
endoproteolysis and enhance Aβ production. A dysfunction
of the receptor can retard the endocytosis of BACE1 and γ-
secretase and thus the production of Aβ (Teng et al., 2010).
The authors further conceived two chimeric receptors to test
whether different receptor endocytic sorting could coordinate
with BACE1 and γ-secretase intracellular trafficking. Results
indicated that different receptors regulate specific substrates
(Teng et al., 2010).
The shedding of APP by BACE1 appears to mainly occur
in early endosomal compartments based on the colocalization
with Rab5, a marker for early endosomes. In this case, the
factors promoting APP or BACE1 internalization to endosomes
can enhance Aβ generation. Reversely, blocking their meeting
decreases Aβ levels (Sannerud et al., 2011). The small GTPase
ARF6 was reported to be an important modulator of BACE1
sorting. The authors created an ARF6 mutant locked in its
ADP-bound state to evaluate the effect on BACE1 and APP
sorting, and found that it blocks the delivery of BACE1 to
early endosomes, suggesting that the GTP hydrolysis of ARF6
is required for the sorting of BACE1 (Sannerud et al., 2011).
They further confirmed that the dileucine motif in the BACE1
carboxyterminal tail is required for the sorting of BACE1 to early
endosomes (Sannerud et al., 2011). While further studies showed
that the recycling endosomes marker Rab11 is colocalized with
internalized BACE1, and the impairment of Rab11 activity
caused accumulation of internalized BACE1 in the soma with a
concomitant decrease of its expression levels in axons (Buggia-
Prévot et al., 2014). The newest study revealed that recycling
endosomes are the major locale of APP and BACE1 convergence
in the dendrites by direct optical assay based on fluorescence
complementation, and in the soma, APP and BACE1 interaction
at the TGN (Das et al., 2016). In summary, the mechanisms
are not clear yet. We draw a profile from the discussion
above to provide a better reference for others (details see
Figure 3).
PERSPECTIVES
BACE1 has broad biological functions in cells, but in the respect
of AD therapy development, scientists are devoted to searching
FIGURE 3 | Interaction between GPCR and BACE1 in neuronal cell. Ligand-bind GPCR can activate G proteins and then stimulate downstream signal
molecules such as PLC, IP3, AC, and cAMP. IP3 can bind to IP3 receptor in the endoplasmic reticulum (ER) leading the release of Ca2+. β-Arrestin can be recruited
to GPCR mediating its desensitization, internalization and G protein independent signaling pathway. GPCR, BACE1, APP, and γ-secretase are synthesized in ER,
and then be transported into plasma membrane, then be guided to endosome. After that these proteins can be sorted to lysosome, proteasome, ER, or back to
plasma membrane. After sequential cut by BACE1 and γ-secretase, APP releases Aβ, which can form oligomers and fibers and finally senile plaque. In addition,
soluble Aβ can promote the phosphorylation of tau, which in turn accelerates the aggregation of Aβ. These factors eventually cause the synapse dysfunction and AD.
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FIGURE 4 | Conventional and Biased ligand-GPCR signal pathway. In conventional ligand-GPCR signal model, the benefit and side effect are thought to turn
on or off at the same time; in biased ligand-GPCR signal model, benefit can be maintained while side effect can be eradicated.
a way of inhibiting its undue cleavage of APP without impacting
other substrates that have important physiological functions in
vivo (Vassar, 2014). Likewise, the most severe side effects due
to absence of γ-secretase activity are caused by deficient Notch
signaling (Selkoe and Kopan, 2003). Researchers found that
GPR3 apparently affects the processing of APP, but not of Notch,
which suggests that GPR3 is an interesting AD therapeutic
target (Thathiah et al., 2009). However, clinical trials carried
out so far have highlighted the difficulties involved in this
type of anti-AD therapy. As evidenced by side effects, likely
due to the ubiquitous nature of the secretases, it might cleave
multiple substrates. Thus, combining potency, selectivity and
the desired safety profiles remains to be a continued challenge.
Hence, there is still a clear need for a novel biochemical
research for the development of potent and selective modulators
targeting BACE1 with properties optimal for central nervous
system therapeutics (Yan and Vassar, 2014). The biased ligands
and allosteric modulators of GPCRs provide the promising
options (Khoury et al., 2014; Violin et al., 2014; Luttrell et al.,
2015).
Biased Ligands
Typically, GPCR activation is involved in broad networks
of signaling pathways, in which most are mediated by G
proteins and β-arrestins (Lefkowitz and Shenoy, 2005). Standard
agonists and antagonists are able to activate or inactivate the
entirety of a receptor’s signaling network. However, biased
ligands (see Figure 4) can selectively engage some signals
while avoiding other signaling pathways mediated by the
same receptor (Wei et al., 2003). Biased ligands provide
functional selectivity for pharmacology and gain increasing
prominence. A handful of biased ligands that are specifically
targeting G protein or β-arrestin signaling pathways have been
discovered (Violin et al., 2014), among which ligands targeting
angiotensin II type 1 receptor, β2AR, opioid receptors are the
hottest. An example is applying biased agonist pilocarpine in
the treatment of AD. Pilocarpine shows positive therapeutic
effects in different AD models, specially, pilocarpine biased Gq
mediates PLC activation over Gs medicated AC stimulation,
whereas non-selective muscarinic agonist carbachol could
equally stimulate Gs and Gq signaling pathways (Fisher et al.,
1993).
Allosteric Modulators
Conventional ligands belong to orthostatic GPCR agonists,
and their cellular effects are mediated through interacting
with the ligand-binding pocket and changing the distribution
of conformation within the receptor ensemble. Allosteric
modulators include ions, ligands, small and large molecules
and protein complexes that modulate the coupling of receptors
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to their effectors by binding to GPCRs at a site other than
the protein’s active sites, which are endogenous ligand binding
sites. The conformational change caused by the allosteric ligands
can selectively alter the reactivity of the receptor towards
certain aspects of the pharmacology of the orthosteric ligand
but not others, which engendered stimulus-bias. According to
the effects on receptor signaling, allosteric ligands have been
divided into two main categories: positive allosteric modulators
(PAMs) and negative allosteric modulators (NAMs; Khoury
et al., 2014). Two drugs have been launched: Sensipar/Mimpra
cinacalcet (Amgen/NPS) is a PAM of calcium-sensing receptor
(CaSR) for hyperparathyroidism treatment; Selzentry/Celsentri
maraviroc (Pfizer) is a NAM of C-C chemokine receptor
type 5 (CCR5) for human immunodeficiency virus (HIV)
therapy. Much work has been done to screen the biased
allosteric modulators for treatment of AD, among which,
modulators targeting mAChRs lead the research. MK-7622
from Merck is a PAM of M1 receptor that is currently
tested in phase II (Conn et al., 2014). The M1 AChR
agonist AF267B can alleviate pathology of AD by shifting the
processing of APP towards the non-amyloidogenic pathway
(Caccamo et al., 2006). TBPB, a systemically M1 AChR
allosteric agonist, was shown to decrease the level of APPβ
(Jones et al., 2008). Data from early optimization and animal
studies are indicative of a healthy pipeline of novel allosteric
modulators that hold promise for the treatment of AD
(Caccamo et al., 2006; Jones et al., 2008; Conn et al.,
2014).
CONCLUDING REMARKS
Collectively, AD is a complex disease and regarding the reported
factors, one solution might not be enough to deal with the
complex condition in vivo (Thathiah and De Strooper, 2009).
It is clear that several GPCRs and GPCR related proteins are
involved in the regulation of BACE1 and the pathogenesis of
AD (Table 2). Nevertheless, progress in this field is hampered
by the difficulties in screening ligands with high specificity
and selectivity and by the adverse side effects of drugs in the
pipeline. Studies have demonstrated that BACE1 and γ-secretase
have other necessary functions in cells, simple segregation
of these secretases will cause a hamper of their ordinary
functions and lead to undesirable side effects, which are so
overwhelming that they prohibit drug’s efficacy and approval.
There is an urgency to understand mechanisms involved in
how GPCRs mediate secretases in AD. According to the
literature, GPCRs might regulate the secretases via G protein-
dependent signaling pathways, or influence the degradation and
internalization of secretases. However, this area is still filled
with unsolved problems that need to be determined by further
investigations. With the development of biased ligands and
allosteric modulators of GPCRs, the therapeutic potential of
GPCRs might be enhanced to provide alternative strategies for
effectively modulating AD pathogenesis with fewer side effects in
the future.
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